| Literature DB >> 31764066 |
Mathieu Maheu-Giroux1, Kimberly Marsh, Carla M Doyle, Arnaud Godin, Charlotte Lanièce Delaunay, Leigh F Johnson, Andreas Jahn, Kouamé Abo, Francisco Mbofana, Marie-Claude Boily, David L Buckeridge, Catherine A Hankins, Jeffrey W Eaton.
Abstract
OBJECTIVE: HIV testing services (HTS) are a crucial component of national HIV responses. Learning one's HIV diagnosis is the entry point to accessing life-saving antiretroviral treatment and care. Recognizing the critical role of HTS, the Joint United Nations Programme on HIV/AIDS (UNAIDS) launched the 90-90-90 targets stipulating that by 2020, 90% of people living with HIV know their status, 90% of those who know their status receive antiretroviral therapy, and 90% of those on treatment have a suppressed viral load. Countries will need to regularly monitor progress on these three indicators. Estimating the proportion of people living with HIV who know their status (i.e. the 'first 90'), however, is difficult.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31764066 PMCID: PMC6919235 DOI: 10.1097/QAD.0000000000002386
Source DB: PubMed Journal: AIDS ISSN: 0269-9370 Impact factor: 4.177
Fig. 1Intercompartmental flow describing HIV testing uptake as a function of HIV status (susceptible versus living with HIV), testing history (never versus ever tested), HIV awareness status, and antiretroviral treatment (ART) status.
List of surveys of with information on the proportion of respondents having ever been tested for HIV (2000–2017) and HIV testing services program data used to calibrate Shiny90 in Côte d’Ivoire, Malawi, and Mozambique.
| Data types | Côte d’Ivoire | Malawi | Mozambique |
| Surveys | MICS 2000 | DHS 2004 | DHS 2003 |
| AIS 2005 | MICS 2006 | MICS 2008* (women only) | |
| DHS 2012 | DHS 2010 | AIS 2009 | |
| MICS 2016 | MICS 2014 | DHS 2011* | |
| PHIA 2017 | DHS 2015 (E) | AIS 2015 (E) | |
| PHIA 2016 (E) | |||
| HIV testing services program data | Direction de l’information, de la planification et de l’évaluation (total tests and number positives for 2010–2017; sex-disaggregated for 2014–2017) | Malawi Integrated HIV Program Report (total tests and number positives 2003–2017; sex-disaggregated for 2013–2017 | National HIV/AIDS Control Program (F. Mbofana, personal communication). (2013–2017; total tests and number positives) |
E: Indicates that the survey was excluded in the out-of-sample validation analyses.
AIS, AIDS Indicator Survey; DHS, Demographic and Health Survey; MICS, Multiple Indicator Cluster Survey; PHIA, Population-based HIV Impact Assessment.
aSurvey does not include serology and estimates of ‘ever tested for HIV’ cannot be stratified by HIV status.
bThe 2017 PHIA survey in Côte d’Ivoire has yet to be released in the public domain. Preliminary results from this survey were used in the model calibration and validation but the relevant point estimates cannot be presented at this time.
cOnly the total number of sex-disaggregated tests is available and the number of positive tests is for both sex combined.
Fig. 2Comparison of calibrated Shiny90 model fits with programmatic and survey data for Côte d’Ivoire (first column), Malawi (second column), and Mozambique (third column) over 2000–2017.
Comparisons of empirical survey estimates of the proportion of individuals aged 15–49 years ever tested for HIV (by sex and HIV status) and self-reported awareness status among PLHIV with Shiny90 model predictions from (a) the fully calibrated model and from out-of-sample predictions that (b) excluded all post-2012 survey and HIV testing services (HTS) program data, (c1) excluded all post-2012 survey data (included sex-combined HTS program data), and (c2) excluded all post-2012 survey data, but included sex-disaggregated HTS data.
| Comparisons | Predictions (95% CrI) | |||||
| Country/outcome | Survey and year | Survey estimates (95% CI) | (a) Full data calibration | (b) Excluding survey and HTS data | (c1) Excluding survey data only (HTS data sex-combined) | (c2) Excluding survey data only (HTS data sex-disaggregated) |
| Côte d’Ivoire | ||||||
| Women ever tested | MICS 2016 | 56% (54–58%) | 52% (51–53%) | 51% (43–65%) | 53% (49–58%) | 53% (51–55%) |
| Men ever tested | MICS 2016 | 35% (32–37%) | 32% (30–33%) | 35% (28–46%) | 36% (31–41%) | 29% (28–31%) |
| WLHIV ever tested | PHIA 2017 | NPD | 74% (70–77%) | 72% (64–83%) | 74% (69–79%) | 74% (73–76%) |
| MLHIV ever tested | PHIA 2017 | NPD | 49% (46–52%) | 52% (44–66%) | 54% (48–61%) | 47% (45–49%) |
| PLHIV aware (’first 90’) | PHIA 2017 | 37% | 58% (53–61%) | 56% (47–70%) | 59% (53–64%) | 57% (55–58%) |
| Malawi | ||||||
| Women ever tested | PHIA 2016 | 83% (82–84%) | 82% (81–83%) | 88% (77–96%) | 91% (90–92%) | 89% (87–90%) |
| Men ever tested | PHIA 2016 | 66% (65–68%) | 67% (66–68%) | 61% (51–76%) | 64% (60–68%) | 68% (66–70%) |
| WLHIV ever tested | PHIA 2016 | 96% (94–97%) | 95% (94–96%) | 98% (93–100%) | 98% (98–99%) | 98% (97–98%) |
| MLHIV ever tested | PHIA 2016 | 89% (86–92%) | 88% (87–89%) | 86% (79–93%) | 87% (84–89%) | 90% (88–91%) |
| PLHIV aware (’first 90’) | PHIA 2016 | 76% (73–78%) | 81% (79–82%) | 81% (73–89%) | 83% (82–85%) | 84% (82–85%) |
| Mozambique | ||||||
| Women ever tested | AIS 2015 | 60% (57–63%) | 62% (61–64%) | 56% (48–67%) | 70% (64–77%) | 65% (62–68%) |
| Men ever tested | AIS 2015 | 38% (35–41%) | 36% (35–38%) | 28% (24–37%) | 38% (32–46%) | 38% (36–40%) |
| WLHIV ever tested | AIS 2015 | 73% (68–77%) | 77% (75–79%) | 74% (67–83%) | 84% (78–89%) | 80% (76–83%) |
| MLHIV ever tested | AIS 2015 | 56% (51–62%) | 55% (51–57%) | 48% (42–56%) | 57% (50–64%) | 57% (53–60%) |
| PLHIV aware (’first 90’) | AIS 2015 | 40% (37–44%) | 63% (60–65%) | 52% (44–63%) | 68% (61–72%) | 66% (61–69%) |
95% CrI, 95% credible interval; 95% CI, 95% confidence interval; HTS, HIV testing services; MICS, multiple indicators cluster survey; MLHIV, men living with HIV; NA, not available; NPD, not in public domain (but included in the calibration); PHIA, population-based HIV impact assessment; WLHIV, women living with HIV.
aAge group is 15–64 years and estimate is not adjusted for presence of antiretroviral metabolites.
Fig. 3Comparisons of calibrated Shiny90 model fits with survey data on proportion of people living with HIV (PLHIV) aged 15–49 years ever tested, model-predicted proportion of PLHIV aware of their status (’first 90’), and survey estimates of awareness status and Spectrum/EPP's antiretroviral therapy (ART) coverage estimates.
Fig. 4Out-of-sample predictions (solid lines) of models calibrated to survey data from 2000 to 2012, excluding all program data, for Côte d’Ivoire, Malawi, and Mozambique, and model predictions for the 2013–2017 period.
Fig. 5Out-of-sample predictions of Shiny90 models calibrated to survey data from 2000 to 2012, including all available program data, for Côte d’Ivoire, Malawi, and Mozambique, and model predictions.
Fig. 6Model predictions of the distribution of the annual total number of HIV-negative tests performed among first-time testers versus repeat testers (top row), distribution of HIV positive tests by awareness status and antiretroviral treatment (ART) status (middle row), and longitudinal trends in HIV testing positivity, yield of new diagnoses, and Spectrum/EPP's estimates of HIV prevalence (aged 15+ years; bottom row); in Côte d’Ivoire (first column), Malawi (second column), and Mozambique (third column).